SEARCH

SEARCH BY CITATION

References

  • Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A.L., Beale, R., Svoboda, P., Laterre, P.F., Simon, S., Light, B., Spapen, H., Stone, J., Seibert, A., Peckelsen, C., De Deyne, C., Postier, R., Pettila, V., Artigas, A., Percell, S.R., Shu, V., Zwingelstein, C., Tobias, J., Poole, L., Stolzenbach, J.C. & Creasey, A.A. (2003) Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. The Journal of the American Medical Association, 290, 238247.
  • Aird, W.C. (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood, 101, 37653777.
  • Andersen, H., Greenberg, D.L., Fujikawa, K., Xu, W., Chung, D.W. & Davie, E.W. (1999) Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proceedings of the National Academy of Sciences of the United States of America, 96, 1118911193.
  • Anderson, R.N. & Smith, B.L. (2005) Deaths: leading causes for 2002. National Vital Statistics Reports, 53, 189.
  • Bae, J.S., Yang, L. & Rezaie, A.R. (2007) Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 28672872.
  • Bajzar, L., Nesheim, M.E. & Tracy, P.B. (1996) The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood, 88, 20932100.
  • Bar-Shavit, R., Kahn, A.J., Mann, K.G. & Wilner, G.D. (1986) Identification of a thrombin sequence with growth factor activity on macrophages. Proceedings of the National Academy of Sciences of the United States of America, 83, 976980.
  • Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W. & Fisher, C.J. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine, 344, 699709.
  • Bertina, R.M., Koeleman, B.P.C., Koster, T., Rosendaal, F.R., Dirven, R.J., De Ronde, H., Van Der Velden, P.A. & Reitsma, P.H. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 6467.
  • Bevers, E.M., Comfurius, P. & Zwaal, R.F.A. (1991) Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Reviews, 5, 146154.
  • Blombäck, B. (1996) Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thrombosis Research, 83, 175.
  • Boskovic, D.S., Giles, A.R. & Nesheim, M.E. (1990) Studies of the role of factor Va in the factor Xa-catalyzed activation of prothrombin, fragment 1.2-prethrombin-2, and dansyl-L-glutamyl- glycyl-L-arginine-meizothrombin in the absence of phospholipid. Journal of Biological Chemistry, 265, 1049710505.
  • Brown, D.A. & London, E. (2000) Structure and function of sphingolipid and cholesterol-rich membrane rafts. Journal of Biological Chemistry, 275, 1722117224.
  • Broze, Jr, G.J. & Higuchi, D.A. (1996) Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood, 88, 38153823.
  • Buller, H.R., Sohne, M. & Middeldorp, S. (2005) Treatment of venous thromboembolism. Journal of Thrombosis and Haemostasis, 3, 15541560.
  • Cantwell, A.M. & Di Cera, E. (2000) Rational design of a potent anticoagulant thrombin. Journal of Biological Chemistry, 275, 3982739830.
  • Cheng, T., Liu, D., Griffin, J.H., Fernandez, J.A., Castellino, F., Rosen, E.D., Fukudome, K. & Zlokovic, B.V. (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nature Medicine, 9, 338342.
  • Cheng, T., Petraglia, A.L., Li, Z., Thiyagarajan, M., Zhong, Z., Wu, Z., Liu, D., Maggirwar, S.B., Deane, R., Fernandez, J.A., LaRue, B., Griffin, J.H., Chopp, M. & Zlokovic, B.V. (2006) Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nature Medicine, 12, 12781285.
  • Comp, P.C., Jacocks, R.M., Ferrell, G.L. & Esmon, C.T. (1982) Activation of protein C in vivo. Journal of Clinical Investigation, 70, 127134.
  • Conway, E.M. & Rosenberg, R.D. (1988) Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Molecular and Cellular Biology, 8, 55885592.
  • Coughlin, S.R. (2000) Thrombin signalling and protease-activated receptors. Nature, 407, 258264.
  • Cutsforth, G.A., Whitaker, R.N., Hermans, J. & Lentz, B.R. (1989) A new model to describe extrinsic protein binding to phospholipid membranes of varying composition: application to human coagulation proteins. Biochemistry, 28, 74537461.
  • Dahlback, B., Carlsson, M. & Svensson, P.J. (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the United States of America, 90, 10041008.
  • Davey, M.G. & Lüscher, E.F. (1967) Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature, 216, 857858.
  • Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G., Tuddenham, E.G. & McVey, J.H. (2003a) Molecular evolution of the vertebrate blood coagulation network. Thrombosis and Haemostasis, 89, 420428.
  • Davidson, C.J., Tuddenham, E.G. & McVey, J.H. (2003b) 450 million years of hemostasis. Journal of Thrombosis and Haemostasis, 1, 14871494.
  • Davie, E.W., Fujikawa, K. & Kisiel, W. (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry, 30, 1036310370.
  • Deguchi, H., Fernandez, J.A., Pabinger, I., Heit, J.A. & Griffin, J.H. (2001) Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood, 97, 19071914.
  • Deguchi, H., Pecheniuk, N.M., Elias, D.J., Averell, P.M. & Griffin, J.H. (2005a) High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation, 112, 893899.
  • Deguchi, H., Bouma, B.N., Middeldorp, S., Lee, Y.M. & Griffin, J.H. (2005b) Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. Journal of Thrombosis and Haemostasis, 3, 935938.
  • Derechin, V.M., Blinder, M.A. & Tollefsen, D.M. (1990) Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition. Journal of Biological Chemistry, 265, 56235628.
  • Dhainaut, J.F., Marin, N., Mignon, A. & Vinsonneau, C. (2001) Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Critical Care Medicine, 29, S4247.
  • Dhainaut, J.F., Yan, S.B., Joyce, D.E., Pettila, V., Basson, B., Brandt, J.T., Sundin, D.P. & Levi, M. (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2, 19241933.
  • Drake, T.A., Cheng, J., Chang, A. & Taylor, F.B. (1993) Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. American Journal of Pathology, 142, 14581470.
  • Ely, E.W., Laterre, P.F., Angus, D.C., Helterbrand, J.D., Levy, H., Dhainaut, J.F., Vincent, J.L., Macias, W.L. & Bernard, G.R. (2003) Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Critical Care Medicine, 31, 1219.
  • Esmon, C.T. (1995) Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. Federation of American Societies for Experimental Biology, 9, 946955.
  • Esmon, C.T. (2003) The Protein C Pathway. Chest, 124, 26S32.
  • Esmon, C.T. (2005) The interactions between inflammation and coagulation. British Journal of Haematology, 131, 417430.
  • Esmon, C.T. & Owen, W.G. (1981) Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proceedings of the National Academy of Sciences of the United States of America, 78, 22492252.
  • Esmon, C.T., Esmon, N.L. & Harris, K.W. (1982) Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. Journal of Biological Chemistry, 257, 79447947.
  • Faioni, E.M., Ferrero, S., Fontana, G., Gianelli, U., Ciulla, M.M., Vecchi, M., Saibeni, S., Biguzzi, E., Cordani, N., Franchi, F., Bosari, S. & Cattaneo, M. (2004) Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Critical Care Medicine, 32, S266S270.
  • Faust, S.N., Levin, M., Harrison, O.B., Goldin, R.D., Lockhart, M.S., Kondaveeti, S., Laszik, Z., Esmon, C.T. & Heyderman, R.S. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. New England Journal of Medicine, 345, 408416.
  • Feinman, R.D., Yuan, A.I., Windwer, S.R. & Wang, D. (1985) Kinetics of the reaction of thrombin and alpha 2-macroglobulin. Journal of Biochemistry, 231, 417423.
  • Feistritzer, C. & Riewald, M. (2005) Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood, 105, 31783184.
  • Feistritzer, C., Sturn, D.H., Kaneider, N.C., Djanani, A. & Wiedermann, C.J. (2003) Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. Journal of Allergy and Clinical Immunology, 112, 375381.
  • Feistritzer, C., Mosheimer, B.A., Sturn, D.H., Riewald, M., Patsch, J.R. & Wiedermann, C.J. (2006) Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. The Journal of Immunology, 176, 10191025.
  • Fernandez, J.A., Kojima, K., Petaja, J., Hackeng, T.M. & Griffin, J.H. (2000) Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cells, Molecules & Diseases, 26, 115123.
  • Fernlund, P. & Stenflo, J. (1982) Amino acid sequence of the light chain of bovine protein C. Journal of Biological Chemistry, 257, 1217012179.
  • Finigan, J.H., Dudek, S.M., Singleton, P.A., Chiang, E.T., Jacobson, J.R., Camp, S.M., Ye, S.Q. & Garcia, J.G.N. (2005) Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. Journal of Biological Chemistry, 280, 1728617293.
  • Fletcher, J.R., McKee, A.E., Mills, M., Snyder, K.C. & Herman, C.M. (1976) Twenty-four hour membrane oxygenation in dogs without anticoagulation. Surgery, 80, 214223.
  • De Fouw, N.J., Van Hinsbergh, V.W., De Jong, Y.F., Haverkate, F. & Bertina, R.M. (1987) The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thrombosis and Haemostasis, 57, 176182.
  • Frenette, P.S., Mayadas, T.N., Rayburn, H., Hynes, R.O. & Wagner, D.D. (1996) Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell, 84, 563574.
  • Fukudome, K. & Esmon, C.T. (1995) Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR). Journal of Biological Chemistry, 270, 55715577.
  • Fukudome, K., Kurosawa, S., Stearns-Kurosawa, D.J., He, X., Rezaie, A.R. & Esmon, C.T. (1996) The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. Journal of Biological Chemistry, 271, 1749117498.
  • Fukudome, K., Ye, X., Tsuneyoshi, N., Tokunaga, O., Sugawara, K., Mizokami, H. & Kimoto, M. (1998) Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. The Journal of Experimental Medicine, 187, 10291035.
  • Galligan, L., Livingstone, W., Volkov, Y., Hokamp, K., Murphy, C., Lawler, M., Fukudome, K. & Smith, O. (2001) Characterization of protein C receptor expression in monocytes. British Journal of Haematology, 115, 408414.
  • Goldsack, N.R., Chambers, R.C., Dabbagh, K. & Laurent, G.J. (1998) Molecules in focus thrombin. The International Journal of Biochemistry & Cell Biology, 30, 641646.
  • Govers-Riemslag, J.W., Janssen, M.P., Zwaal, R.F. & Rosing, J. (1994) Prothrombin activation on dioleoylphosphatidylcholine membranes. European Journal of Biochemistry, 220, 131138.
  • Grey, S.T. & Hancock, W.W. (1996) A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. Journal of Immunology, 156, 22562263.
  • Griffin, J.H., Kojima, K., Banka, C.L., Curtiss, L.K. & Fernandez, J.A. (1999) High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. The Journal of Clinical Investigation, 103, 219227.
  • Griffin, J.H., Fernández, J.A. & Deguchi, H. (2001) Plasma lipoproteins, hemostasis and thrombosis. Thrombosis and Haemostasis, 86, 386394.
  • Gruber, A. & Griffin, J.H. (1992) Direct detection of activated protein C in blood from human subjects. Blood, 79, 23402348.
  • Gruber, A., Marzec, U.M., Bush, L., Di Cera, E., Fernandez, J.A., Berny, M.A., Tucker, E.I., McCarty, O.J.T., Griffin, J.H. & Hanson, S.R. (2007) Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood, 109, 37333740.
  • Gu, M.D. (2003) The Taiji diagram: a meta-sign in Chinese thought. Journal of Chinese Philosophy, 30, 195218.
  • Gu, J.-M., Katsuura, Y., Ferrell, G.L., Grammas, P. & Esmon, C.T. (2000) Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood, 95, 16871693.
  • Guo, H., Liu, D., Gelbard, H., Cheng, T., Insalaco, R., Fernandez, J.A., Griffin, J.H. & Zlokovic, B.V. (2004) Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron, 41, 563572.
  • Hamberg, M., Svensson, J. & Samuelsson, B. (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America, 72, 29942998.
  • Hamilton, J.R., Moffatt, J.D., Frauman, A.G. & Cocks, T.M. (2001) Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. Journal of Cardiovascular Pharmacology, 38, 108119.
  • Heeb, M.J. & Griffin, J.H. (1988) Physiologic inhibition of human activated protein C by alpha 1- antitrypsin. Journal of Biological Chemistry, 263, 1161311616.
  • Hoogendoorn, H., Toh, C.H., Nesheim, M.E. & Giles, A.R. (1991) Alpha 2-macroglobulin binds and inhibits activated protein C. Blood, 78, 22832290.
  • Hurtado, V., Montes, R., Gris, J.-C., Bertolaccini, M.L., Alonso, A., Martinez-Gonzalez, M.A., Khamashta, M.A., Fukudome, K., Lane, D.A. & Hermida, J. (2004) Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood, 104, 13691374.
  • Ishihara, H., Connolly, A.J., Zeng, D., Kahn, M.L., Wu Zheng, Y., Timmons, C., Tram, T. & Coughlin, S.R. (1997) Protease-activated receptor 3 is a second thrombin receptor in humans. Nature, 386, 502506.
  • Iwaki, T., Cruz, D.T., Martin, J.A. & Castellino, F.J. (2005) A cardioprotective role for the endothelial protein C receptor in lipopolysaccharide-induced endotoxemia in the mouse. Blood, 105, 23642371.
  • Jesty, J. (1986) The kinetics of inhibition of alpha-thrombin in human plasma. Journal of Biological Chemistry, 261, 1031310318.
  • Joyce, D.E., Gelbert, L., Ciaccia, A., DeHoff, B. & Grinnell, B.W. (2001) Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. Journal of Biological Chemistry, 276, 1119911203.
  • Kadir, A.R., Economides, D.L., Sabin, C.A., Owens, D. & Lee, C.A. (1999) Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Journal of Thrombosis and Haemostasis, 82, 14561461.
  • Kerlin, B.A., Yan, S.B., Isermann, B.H., Brandt, J.T., Sood, R., Basson, B.R., Joyce, D.E., Weiler, H. & Dhainaut, J.-F. (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood, 102, 30853092.
  • Kisiel, W., Canfield, W.M., Ericsson, L.H. & Davie, E.W. (1977) Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry, 16, 58245831.
  • Kurosawa, S., Esmon, C.T. & Stearns-Kurosawa, D.J. (2000) The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. The Journal of Immunology, 165, 46974703.
  • Laszik, Z., Mitro, A., Taylor, Jr, F.B., Ferrell, G. & Esmon, C.T. (1997) Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation, 96, 36333640.
  • Lee, R. (2001) Factor V Leiden: a clinical review. The American Journal of the Medical Sciences, 322, 88102.
  • Lentz, B.R. (2003) Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Progress in Lipid Research, 42, 423438.
  • Lentz, S.R., Tsiang, M. & Sadler, J.E. (1991) Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood, 77, 542550.
  • Li, W., Zheng, X., Gu, J., Hunter, J., Ferrell, G.L., Lupu, F., Esmon, N.L. & Esmon, C.T. (2005) Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. Journal of Thrombosis and Haemostasis, 3, 13511359.
  • Liu, D., Cheng, T., Guo, H., Fernandez, J.A., Griffin, J.H., Song, X. & Zlokovic, B.V. (2004) Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nature Medicine, 10, 13791383.
  • Ludeman, M.J., Kataoka, H., Srinivasan, Y., Esmon, N.L., Esmon, C.T. & Coughlin, S.R. (2005) PAR1 cleavage and signaling in response to activated protein C and thrombin. Journal of Biological Chemistry, 280, 1312213128.
  • Mann, K.G., Brummel, K. & Butenas, S. (2003) What is all that thrombin for? Journal of Thrombosis and Haemostasis, 1, 15041514.
  • Marciniak, E., Wilson, H.D. & Marlar, R.A. (1985) Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood, 65, 1520.
  • Marlar, R.A. & Neumann, A. (1990) Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Seminars in Thrombosis and Hemostasis, 16, 299309.
  • Marlar, R.A., Kleiss, A.J. & Griffin, J.H. (1982) Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood, 59, 10671072.
  • Maruyama, I., Salem, H.H., Ishii, H. & Majerus, P.W. (1985) Human thrombomodulin is not an efficient inhibitor of the procoagulant activity of thrombin. Journal of Clinical Investigation, 75, 987991.
  • Medina, P., Navarro, S., Estellés, A., Vayá, A., Woodhams, B., Mira, Y., Villa, P., Migaud-Fressart, M., Ferrando, F., Aznar, J., Bertina, R.M. & España, F. (2004) Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Journal of Thrombosis and Haemostasis, 91, 905911.
  • Minami, T., Sugiyama, A., Wu, S.Q., Abid, R., Kodama, T. & Aird, W.C. (2004) Thrombin and phenotypic modulation of the endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 4153.
  • De Moerloose, P. & Boehlen, F. (2007) Inherited thrombophilia in arterial disease: a selective review. Seminars in Hematology, 44, 106113.
  • Montes, R., Hurtado, V., Alonso, A., Foco, L., Zonzin, P., Mannucci, P.M. & Hermida, J. (2005) Autoantibodies against the endothelial receptor of protein C are associated with acute myocardial infarction in young women. Journal of Thrombosis and Haemostasis, 3, 14541458.
  • Moore, K.L., Andreoli, S.P., Esmon, N.L., Esmon, C.T. & Bang, N.U. (1987) Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. Journal of Clinical Investigation, 79, 124130.
  • Mosnier, L.O., Zlokovic, B.V. & Griffin, J.H. (2007) The cytoprotective protein C pathway. Blood, 109, 31613172.
  • Moyer, M.P., Tracy, R.P., Tracy, P.B., Veer, C.V., Sparks, C.E. & Mann, K.G. (1998) Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 458465.
  • Nick, J.A., Coldren, C.D., Geraci, M.W., Poch, K.R., Fouty, B.W., O’Brien, J., Gruber, M., Zarini, S., Murphy, R.C., Kuhn, K., Richter, D., Kast, K.R. & Abraham, E. (2004) Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood, 104, 38783885.
  • Van Nieuw Amerongen, G.P., Draijer, R., Vermeer, M.A. & Van Hinsbergh, V.W.M. (1998) Transient and prolonged increase in endothelial permeability induced by histamine and thrombin: role of protein kinases, calcium, and RhoA. Circulation Research, 83, 11151123.
  • Oganesyan, V., Oganesyan, N., Terzyan, S., Qu, D., Dauter, Z., Esmon, N.L. & Esmon, C.T. (2002) The crystal structure of the endothelial protein C receptor and a bound phospholipid. Journal of Biological Chemistry, 277, 2485124854.
  • Oka, S., Gabazza, E.C., Taguchi, Y., Yamaguchi, M., Nakashima, S., Suzuki, K., Adachi, Y. & Imoto, I. (2000) Role of activated protein C in helicobacter pylori-associated gastritis. Infection and Immunity, 68, 28632869.
  • Okajima, K., Koga, S., Kaji, M., Inoue, M., Nakagaki, T., Funatsu, A., Okabe, H., Takatsuki, K. & Aoki, N. (1990) Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Journal of Thrombosis and Haemostasis, 63, 4853.
  • Osterud, B. & Rapaport, S.I. (1977) Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proceedings of the National Academy of Sciences of the United States of America, 74, 52605264.
  • Palareti, G., Legnani, C., Cosmi, B., Valdre, L., Lunghi, B., Bernardi, F. & Coccheri, S. (2003) Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation, 108, 313318.
  • Perez-Casal, M., Downey, C., Fukudome, K., Marx, G. & Toh, C.H. (2005) Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood, 105, 15151522.
  • Powell, M.G., Hedlin, A.M., Cerskus, I., Kakis, G., Prudham, D. & Rosenrot, P. (1984) Effects of oral contraceptives on lipoprotein lipids: a prospective study. Obstetrics & Gynecology, 63, 764770.
  • Price, D.T. & Ridker, P.M. (1997) Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Annals of Internal Medicine, 127, 895903.
  • Prigozy, T.I., Naidenko, O., Qasba, P., Elewaut, D., Brossay, L., Khurana, A., Natori, T., Koezuka, Y., Kulkarni, A. & Kronenberg, M. (2001) Glycolipid antigen processing for presentation by CD1d molecules. Science, 291, 664667.
  • Qu, D., Wang, Y., Esmon, N.L. & Esmon, C.T. (2007) Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. Journal of Thrombosis and Haemostasis, 5, 395402.
  • Regan, L.M., Stearns-Kurosawa, D.J., Kurosawa, S., Mollica, J., Fukudome, K. & Esmon, C.T. (1996) The endothelial cell protein C receptor inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. Journal of Biological Chemistry, 271, 1749917503.
  • Rezaie, A.R. (2001) Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Journal of Biological Chemistry, 276, 1556715570.
  • Ridker, P. (2004) Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. The American Heart Hospital Journal, 2, 49.
  • Riewald, M. & Ruf, W. (2005) Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. Journal of Biological Chemistry, 280, 1980819814.
  • Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M. & Ruf, W. (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 296, 18801882.
  • Rosenberg, R.D. & Rosenberg, J.S. (1984) Natural anticoagulant mechanisms. Journal of Clinical Investigation, 74, 16.
  • Rosing, J., Middeldorp, S., Curvers, J., Thomassen, M.C.L.G., Nicolaes, G.A.F., Meijers, J.C.M., Bouma, B.N., Buller, H.R., Prins, M.H. & Tans, G. (1999) Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. The Lancet, 354, 20362040.
  • Rota, S., McWilliam, N.A., Baglin, T.P. & Byrne, C.D. (1998) Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood, 91, 508515.
  • Ruf, W. (2005) Is APC activation of endothelial cell PAR1 important in severe sepsis?: Yes. Journal of Thrombosis and Haemostasis, 3, 19121914.
  • Sakata, Y. & Aoki, N. (1982) Significance of cross-linking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. Journal of Clinical Investigation, 69, 536542.
  • Sapet, C., Simoncini, S., Loriod, B., Puthier, D., Sampol, J., Nguyen, C., Dignat-George, F. & Anfosso, F. (2006) Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood, 108, 18681876.
  • Saposnik, B., Reny, J.-L., Gaussem, P., Emmerich, J., Aiach, M. & Gandrille, S. (2004) A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood, 103, 13111318.
  • Scaldaferri, F., Sans, M., Vetrano, S., Graziani, C., De Cristofaro, R., Gerlitz, B., Repici, A., Arena, V., Malesci, A., Panes, J., Grinnell, B.W. & Danese, S. (2007) Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. The Journal of Clinical Investigation, 117, 19511960.
  • Schutgens, R.E.G., Ackermark, P., Haas, F.J.L.M., Nieuwenhuis, H.K., Peltenburg, H.G., Pijlman, A.H., Pruijm, M., Oltmans, R., Kelder, J.C. & Biesma, D.H. (2003) Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. Circulation, 107, 593597.
  • Scully, M.F., Toh, C.H., Hoogendoorn, H., Manuel, R.P., Nesheim, M.E., Solymoss, S. & Giles, A.R. (1993) Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 69, 448453.
  • Shen, L. & Lorand, L. (1983) Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. Journal of Clinical Investigation, 71, 13361341.
  • Shibata, M., Kumar, S.R., Amar, A., Fernandez, J.A., Hofman, F., Griffin, J.H. & Zlokovic, B.V. (2001) Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation, 103, 17991805.
  • Shorr, A., Bernard, G., Dhainaut, J.-F., Russell, J., Macias, W., Nelson, D. & Sundin, D. (2006) Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Critical Care, 10, R92.
  • Simons, K. & Ikonen, E. (1997) Functional rafts in cell membranes. Nature, 387, 569572.
  • Smirnov, M.D. & Esmon, C.T. (1994) Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. Journal of Biological Chemistry, 269, 816819.
  • Stearns-Kurosawa, D.J., Kurosawa, S., Mollica, J.S., Ferrell, G.L. & Esmon, C.T. (1996) The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proceedings of the National Academy of Sciences of the United States of America, 93, 1021210216.
  • Stearns-Kurosawa, D.J., Swindle, K., D’Angelo, A., Della Valle, P., Fattorini, A., Caron, N., Grimaux, M., Woodhams, B. & Kurosawa, S. (2002) Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood, 99, 526530.
  • Sturn, D.H., Kaneider, N.C., Feistritzer, C., Djanani, A., Fukudome, K. & Wiedermann, C.J. (2003) Expression and function of the endothelial protein C receptor in human neutrophils. Blood, 102, 14991505.
  • Suzuki, K., Deyashiki, Y., Nishioka, J., Kurachi, K., Akira, M., Yamamoto, S. & Hashimoto, S. (1987) Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. Journal of Biological Chemistry, 262, 611616.
  • Takano, S., Kimura, S., Ohdama, S. & Aoki, N. (1990) Plasma thrombomodulin in health and diseases. Blood, 76, 20242029.
  • Taylor, F.B. & Kinasewitz, G. (2004) Activated protein C in sepsis. Journal of Thrombosis and Haemostasis, 2, 708717.
  • Taylor, F.B.J., Chang, A., Esmon, C.T., D’Angelo, A., Vigano-D’Angelo, S. & Blick, K.E. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. The Journal of Clinical Investigation, 79, 918925.
  • Taylor, F.B.J., Stearns-Kurosawa, D.J., Kurosawa, S., Ferrell, G., Chang, A.C.K., Laszik, Z., Kosanke, S., Peer, G. & Esmon, C.T. (2000) The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood, 95, 16801686.
  • Taylor, F.B.J., Peer, G.T., Lockhart, M.S., Ferrell, G. & Esmon, C.T. (2001) Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood, 97, 16851688.
  • Tesfamariam, B., Allen, G.T., Normandin, D. & Antonaccio, M.J. (1993) Involvement of the “tethered ligand” receptor in thrombin-induced endothelium-mediated relaxations. American Journal of Physiology, 265, H17441749.
  • Toh, C.H. (1997) Anticoagulants for venous thrombosis. Postgraduate Medical Journal, 73, 283285.
  • Vehar, G.A. & Davie, E.W. (1980) Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry, 19, 401410.
  • Vincent, J.L., Bernard, G.R., Beale, R., Doig, C., Putensen, C., Dhainaut, J.F., Artigas, A., Fumagalli, R., Macias, W., Wright, T., Wong, K., Sundin, D.P., Turlo, M.A. & Janes, J. (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Critical Care Medicine, 33, 22662277.
  • De Visser, M.C.H., Rosendaal, F.R. & Bertina, R.M. (1999) A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood, 93, 12711276.
  • Warren, B.L., Eid, A., Singer, P., Pillay, S.S., Carl, P., Novak, I., Chalupa, P., Atherstone, A., Penzes, I., Kubler, A., Knaub, S., Keinecke, H.-O., Heinrichs, H., Schindel, F., Juers, M., Bone, R.C. & Opal, S.M. (2001) High-dose antithrombin III in severe sepsis: a randomized controlled trial. The Journal of the American Medical Association, 286, 18691878.
  • Waselenko, J.K., Nace, M.C. & Alving, B. (1998) Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Seminars in Thrombosis and Hemostasis, 24, 3339.
  • Wu, S.-Q. & Aird, W.C. (2005) Thrombin, TNF-{alpha}, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells. The American Journal of Physiology. Heart and Circulatory Physiology, 289, H873885.
  • Xu, J., Qu, D., Esmon, N.L. & Esmon, C.T. (2000) Metalloproteolytic release of endothelial cell protein C receptor. Journal of Biological Chemistry, 275, 60386044.
  • Xue, M., Campbell, D., Sambrook, P.N., Fukudome, K. & Jackson, C.J. (2005) Endothelial protein C receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C. Journal of Investigative Dermatology, 125, 12791285.
  • Xue, M., March, L., Sambrook, P.N., Fukudome, K. & Jackson, C.J. (2007) Endothelial protein C receptor is over-expressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes. Annals of the Rheumatic Diseases, 66, 15741580.
  • Yan, S.B., Helterbrand, J.D., Hartman, D.L., Wright, T.J. & Bernard, G.R. (2001) Low levels of protein C are associated with poor outcome in severe sepsis. Chest, 120, 915922.
  • Yegneswaran, S., Deguchi, H. & Griffin, J.H. (2003) Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human and bovine activated protein C with negatively charged phospholipid vesicles. Journal of Biological Chemistry, 278, 1461414621.
  • Yin, Y.-J., Salah, Z., Grisaru-Granovsky, S., Cohen, I., Even-Ram, S.C., Maoz, M., Uziely, B., Peretz, T. & Bar-Shavit, R. (2003) Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 940944.